by EpicentRx | Oct 18, 2018 | Conferences
October 2018, San Antonio, Texas Abstract: Initial clinical and advanced imaging outcomes from a multi-institutional phase I dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases
by EpicentRx | Jun 18, 2018 | Conferences
June 2018, Chicago, Illinois Abstract: QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer
by EpicentRx | May 2, 2018 | 2018 & Prior, Press Releases
SAN DIEGO, May 2, 2018 — EpicentRx, a San Diego biotechnology company developing a next-generation immunotherapy platform of viruses that infect and kill cancer cells for the treatment of several tumor types, has developed the first ever series of oncolytic...
by EpicentRx | Feb 18, 2018 | Conferences
February 2018, San Francisco, California Abstract: Sensitization of neuroendocrine prostate cancer by RRx-001
by EpicentRx | Feb 18, 2018 | Conferences
February 2018, Virtual Abstract: RRx-001 is a phase III aerospace-derived small molecule that immunonormalizes the tumor microenvironment
